Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice

Carcinogenesis

Volumn 28, Issue 6, 2007, Pages 1217-1223

  Mai, Zhiming ^a   Blackburn, George L ^a   Zhou, Jin Rong ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; GENISTEIN; ISOFLAVONE; PLANT MEDICINAL PRODUCT; PROTEIN PS2; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOYBEAN;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ESTROGENS; FEMALE; HUMANS; MICE; MICE, SCID; PHYTOTHERAPY; SOYBEANS; TAMOXIFEN;

EID: 34447296461     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm004     Document Type: Article

References (33)

1. American Cancer Society.Cancer Facts and Figures 2005 American Cancer Society, Atlanta, GA: American Cancer Society.
2. Fisher,B. et al. (1996) Five vs more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor positive tumors. J. Natl Cancer Inst., 88, 1529-1542.
3. Fisher,B. et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst., 90, 1371-1388.
4. Henderson,B.E. et al. (1991) The international variation in breast cancer rates: An epidemiological assessment. Breast Cancer Res. Treat., 18, S11-S17.
5. Ziegler,R.G. et al. (1993) Migration patterns and breast cancer risk in Asian-American women. J. Natl Cancer Inst., 85, 1819-1827.
6. Messina,M.J. et al. (1994) Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr. Cancer, 21, 113-131.
7. Kennedy,A.R. (1995) The evidence for soybean products as cancer preventive agents. J. Nutr., 125, 733S-743S.
8. Rao,A.V. et al. (1995) Saponins as anticarcinogens. J. Nutr. 125, 717s-724s.
9. Shamsuddin,A.M. (1995) Inositol phosphates have novel anticancer function. J. Nutr., 125, 725s-732s.
10. Newton,K.M. et al. (2002) Use of alternative therapies for menopause symptoms: Results of a population-based survey. Obstet. Gynecol., 100, 18-25.
11. Messina,M.J. et al. (2001) Soy for breast cancer survivors: A critical review of the literature. J. Nutr., 131, 3095S-3108S.
12. Brzezinski,A. et al. (1999) Phytoestrogens: The "natural selective estrogen receptor modulators? Eur. J. Obstet. Gynecol. Reprod. Biol., 85, 47-51.
13. Carusi,D. (2000) Phytoestrogens as hormone replacement therapy: An evidence-based approach. Prim. Care Update Ob. Gyns., 7, 253-259.
14. Jones,J.L. et al. (2002) Genistein inhibits tamoxifen effects on cell proliferation and cell cycle arrest in T47D breast cancer cells. Am. Surg., 68, 575-578.
15. Ju,Y.H. et al. (2002) Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res., 62, 2474-2477.
16. Liu,B. et al. (2005) Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res, 65 879-886.
17. Seo,H.S. et al. (2006) Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res. Treat, 99, 121-134.
18. Constantinou,A.I. et al. (2005) The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. Eur. J. Cancer, 41, 647-654.
19. Shen,F. et al. (1999) Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells. Anticancer Res., 19, 1657-1662.
20. Tanos,V. et al. (2002) Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Eur. J. Obstet. Gynecol. Reprod. Biol., 102, 188-194.
21. Chen,J. et al. (2004) Potential beneficial metabolic interactions between tamoxifen and isoflavones via cytochrome P450-mediated pathways in female rat liver microsomes. Pharm. Res., 21, 2095-2104.
22. Zhou,J.-R. et al. (2004) Combined inhibition of estrogen-dependent human breast carcinoma by soy and tea bioactive components in mice. Int. J. Cancer, 108, 8-14.
23. Zhou,J.-R. et al. (1999) Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J. Nutr., 129, 1628-1635.
24. Zhou,J.-R. et al. (1998) The inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res., 58, 5231-5238.
25. Steel,R.G.D. et al. (1980) Principles and Procedures of Statistics: A Biometrical Approach. McGraw-Hill book Company, Inc, New York, NY.
26. Yokoyama,Y. et al. (2000) Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth. Cancer Res., 60, 2190-2196.
27. Chou,T.C. et al. (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22, 27-55.
28. Soule,H.D. et al. (1980) Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice. Cancer Lett., 10, 177-189.
29. Normanno,N. et al. (2002) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol., 13, 65-72.
30. Lamartiniere,C.A. et al. (2002) Genistein chemoprevention: Timing and mechanisms of action in murine mammary and prostate. J. Nutr., 132, 552S-558S.
31. El-Zarruk,A.A. et al. (1999) The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R tyrosine kinase. Cancer Lett., 142, 185-193.
32. Cotroneo,M.S. et al. (2002) Genistein action in the prepubertal mammary gland in a chemoprevention model. Carcinogenesis, 23 1467-1474.
33. Hiscox,S. et al. (2004) Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin. Exp. Metastasis, 21, 201-212.